



ASX / MEDIA RELEASE

17TH December 2010

Compumedics wins another major EEG LTM deal

First major milestone achieved with entry strategy into the US (LTM) market

CHARLOTTE, N.C., Dec. 13, 2010 /PRNewswire/ -- Compumedics USA, Inc. (CMP.ASX) today announced a major milestone for its new NEUVO® Long Term Monitoring (LTM) EEG (electroencephalography) system. The University of South Alabama Medical Center (USAMC) in Mobile Alabama has purchased the new Compumedics NEUVO® LTM EEG systems for its Long Term Epilepsy Monitoring Unit. This purchase represents another major milestone in Compumedics' entry into the global \$250 million LTM/Neurophysiology market and is the first major sale in the US into this market place.

The sale, with an order value of more than USD400k, will deliver Compumedics NEUVO® LTM EEG systems that can record 256 individual channels of high-density, EEG data on a single patient for days or weeks at a time. The Compumedics digital amplifier technology is superior to existing competitors and provides Compumedics a unique point of differentiation as part of its entry strategy into this new market. It is important because higher quality brain recordings and more precise brain analysis can improve patient outcomes.

The Epilepsy Foundation estimates that more than 3 million people in the US are affected by epilepsy with 200,000 new cases each year. Of these 10% may require surgical brain resections to control debilitating seizure activity. There are more than 60 dedicated Epilepsy Centers in the US that provide advanced diagnostic and treatment services for epilepsy and many more hospitals that offer more limited epilepsy management services.

In addition USAMC will use Compumedics Neuroscan® CURRY® software to integrate brain imaging from patients' MRI and CT scans with the EEG recordings, helping identify the source of epileptic seizures in preparation for surgical intervention. Dr. Dean Naritoku, Professor and Chair of Neurology, said,

"We evaluated solutions from other vendors but none could provide the integrated solution that Compumedics offered to help guide us in surgically treating this patient population."

The University of South Alabama Medical Center is an acute care hospital and a major referral center for south Alabama, southern Mississippi and the panhandle of Florida. Compumedics has made significant investments in product development targeting the neuro-diagnostics market to

For personal use only

leverage its expertise in high-end amplifier design and physiologic signal processing. The combination of the NEUVO® LTM EEG system and the CURRY® neuroimaging analysis software suite makes it easier for epileptologists and neurosurgeons to identify which specific regions in the brain are most likely to be the cause of severe seizure activity in an afflicted patient. Jeff Kuznia, Compumedics USA's vice-president of sales and marketing, said,

"This sale represents one of many opportunities we are pursuing in the LTM-EEG market. The overwhelmingly positive reception for Compumedics products at the annual medical conference of the American Epilepsy Society recently held in San Antonio, Texas reflects the growing appreciation for the advanced solutions Compumedics provides."

Dr. David Burton, chairman and chief executive officer of Compumedics Group, commented,

"The establishment of centres of excellence such as the University of South Alabama Medical Center is an important milestone for our Company and reinforces our commitment to our customers and the patient's they serve. The increasing market acceptance of our new Neuvo long term monitoring (LTM) EEG product range is the culmination of one of Compumedics most significant projects to date, whereby we have integrated our best of class acquisition technology with premier Curry brain analysis software to produce a degree of signals quality, coupled with analysis precision and sophistication, previously not accessible within the clinical application domain. The success of our LTM EEG product roll-out further reinforces our strategy to augment our traditional technology focus by expanding our global sales force, to accommodate the LTM EEG and routine EEG patient monitoring market. This market collectively represents a sales expansion opportunity equivalent to our existent core sleep diagnostics business."

About Compumedics Compumedics Limited, was founded in **1987** by current Chairman/CEO Dr. David Burton and today is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In **1987** Compumedics established Asia Pacific's first fully computerized sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices. In **1995** the company was selected to supply equipment to the US Sleep Heart Health Study, the world's largest sleep study of its kind, with over 8,000 participants scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe its products are distributed in over 50 countries. In **1998** Compumedics was awarded the overall Australian Exporter of the Year. In **2000** Compumedics was listed on the Australian Stock Exchange. In **2002**, Compumedics acquired US-based **Neuroscan** - the world's leading supplier of instruments for brain research. In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. In **2003** Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. In **2004**, Compumedics acquired Germany-based **DWL Elektronische GmbH**, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. In **2006**, Compumedics was awarded the Frost and Sullivan Technology Leadership award for its innovative Somté® recorder product. In **2007**, Compumedics and its Chairman were inducted into the Victorian Manufacturing Hall of Fame. In **2008** the DWL division received a top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics Compumedics sales have grown more than 4-fold from \$9 million (1999) to \$39 million (2008). In **2009** Compumedics was awarded a design award for its GRAEL® PSG/EEG premium laboratory-based product. In **2010** Compumedics was recognized by the Australian Innovation Government and Industry body as one of Australia's Top 100 Health Innovators through its' world leading devices for sleep diagnostics. **For further background please visit: www.compumedics.com**

For further information please contact:

Compumedics CEO/Chairman: Dr. David Burton 61-3-8420-7300; dburton@compumedics.com.au

Bourse Communications: Mr. Rod North T: 03 9510 8309 M: 0408 670 706 E:rod@boursecommunications.com.au

Investors: CMP.ASX (ASX.COM)